Navigation Links
Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease

CRANBURY, N.J., Sept. 30 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced it plans to initiate a Phase 1 study of AT2220 (1-deoxynojirimycin HCl), its investigational drug in development for the treatment of Pompe Disease. The primary objective of this study is to evaluate the pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. The U.S. Food and Drug Administration (FDA) has agreed to Amicus' proposal for the Phase 1 study and subsequently converted the clinical hold of AT2220 to a partial hold to allow the conduct of this study.

In June 2008, the Company announced the commencement of a Phase 2 clinical trial of AT2220 in adults with Pompe disease based on data from both preclinical and Phase 1 studies. In February 2009, the Company announced it had suspended enrollment after two patients enrolled in the trial experienced serious adverse events that were probably related to treatment with AT2220. The AT2220 Investigational New Drug application (IND) was subsequently placed on clinical hold by the FDA.

The Company has completed a thorough evaluation of all data from these two subjects and has completed additional preclinical studies of AT2220. Based on these data, the Company proposed the planned Phase 1 study to FDA in order to further evaluate the pharmacokinetics of AT2220 in muscle, the key target tissue in Pompe disease. This study will be an open label, single dose study and will commence in the fourth quarter of this year. The Company expects data from this trial to be available in the first quarter of 2010. Based on the results of this study, the Company will determine the appropriate next steps for the program working in close collaboration with the FDA.

One of the recently completed preclinical studies evaluated the effects of various doses and regimens of AT2220 on glycogen reduction in an appropriate transgenic mouse model of Pompe disease. Preliminary results of this study demonstrate consistent glycogen reduction across a range of different tissues, including heart, diaphragm and multiple skeletal muscles. Glycogen is the substrate that accumulates in the cells of patients with Pompe disease, which is believed to result in the clinical symptoms of the disease. The Company expects to present the results of this and other preclinical studies at appropriate scientific conferences in 2010.

Additionally, Amicus continues to be encouraged by the results of preclinical studies designed to evaluate the use of AT2220 in combination with enzyme replacement therapy (ERT). The Company expects to report additional data from these studies at scientific conferences in 2010.

About Pompe Disease

Pompe disease affects an estimated 5,000 to 10,000 individuals world-wide and is clinically heterogeneous in the age of onset, the extent of organ involvement, and the rate of progression. The early onset form of the disease is the most severe, progresses most rapidly, and is characterized by musculoskeletal, pulmonary, gastrointestinal, and cardiac symptoms that usually lead to death from cardio-respiratory failure between 1 and 2 years of age. The late onset form of the disease begins between childhood and adulthood and has a slower rate of progression that is characterized by musculoskeletal and pulmonary symptoms that usually lead to progressive muscle weakness and respiratory insufficiency. A high majority of people with Pompe disease have the late onset form. The U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for the active ingredient in AT2220 in the United States.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of Amicus' candidate drug product, AT2220 (1-deoxynojirimycin HCl), the timing and reporting of results from preclinical studies and clinical trials evaluating Amicus' candidate drug products, and the timing of updates on the interactions with the FDA on the AT2220 program. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to reach final agreement with regulatory agencies on the lifting of the clinical hold on the AT2220 program; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


    SOURCE Amicus Therapeutics


SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, 2015 ... company developing next generation vaccines based on the ... into an exclusive worldwide licensing agreement with Astellas ... or prevention of any and all allergic diseases ... Therapeutics will receive an upfront payment of $300 ...
(Date:10/8/2015)... UK (PRWEB) , ... October 08, 2015 , ... Researchers ... literally see inside the living brain, providing a new tool to study how diseases ... is reported by Woo June Choi and Ruikang Wang of the UW Department of ...
(Date:10/8/2015)... Pa. , Oct. 8, 2015  Clarkston Consulting, ... the call for applications for the 2016 Clarkston Scholars ... a life sciences related field of study, a $10,000 ... selected Clarkston Scholar will receive exposure to the life ... in Pennsylvania Bio events over the course of the ...
(Date:10/8/2015)... , Oct. 8, 2015  Today, DuPont and ... for genome editing, jointly announced a strategic alliance. ... cross-licensed their respective patent portfolios, with DuPont receiving ... in major row crops, and non-exclusive rights in ... --> --> In ...
Breaking Biology Technology:
... RICHMOND, Va., June 20 Insmed Inc. (Nasdaq:,INSM), ... that it intends to request a hearing before ... an earlier Staff Determination,to delist the Company,s common ... received a letter from The NASDAQ Stock Market ...
... Initiated to Find Suitable Candidate, WESLEY CHAPEL, ... today that Eran Rotem, its Chief,Financial Officer, who ... June 2008. The Company has initiated search for ... this position., Ram Ajjarapu commented: "We appreciate ...
... Germany – June 20, 2008 / b3c newswire ... contract manufacturing organization (CMO) for the development and ... of a 2,500 L multi-process production suite. Hence, ... with volumes of 30, 250, 500 and 2,500 ...
Cached Biology Technology:
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... Comparative Biology (SICB), one of the oldest and most ... at the Hilton San Francisco, Union Square, in San ... than 1,500 scientists will present the latest research on ... a rich assortment of news and feature possibilities. ...
... in biology are given the freedom to play, dabble in ... worry about getting "good" results? In the case ... level of new knowledge and publications generated by student-and-faculty teams. ... magazine, several scientists who have directed the Physiology course detail ...
... Chinese research team, led by Beijing Forestry University, BGI, Beijing ... has completed the first genomic sequence of Prunus mume ... the deeper understanding of Rosaceae evolution and provides an invaluable ... was published online today in Nature Communication ., As ...
Cached Biology News:
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
AK6 Antibody...
Biology Products: